Vasiliki Savva, Ioannis Fragkioudakis, Dimitra Sakellari
{"title":"环氧化酶-2 (COX-2)基因单核苷酸多态性与牙周病的关系——荟萃分析的系统综述及其对个性化牙科的影响","authors":"Vasiliki Savva, Ioannis Fragkioudakis, Dimitra Sakellari","doi":"10.3390/jpm15080351","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Genetic polymorphisms in the cyclooxygenase-2 (COX-2) gene may contribute to individual susceptibility to periodontal disease. A meta-analysis assessed the association between three COX-2 single-nucleotide polymorphisms (SNPs) namely, -765 G/C (rs20417), -1195 G/A (rs689466), and 8473 T/C (rs5275), and the risk of CP. <b>Methods:</b> Following the PRISMA 2020 guidelines, we conducted a comprehensive search of five electronic databases and additional sources. The eligible studies were observational (case-control or cohort) with genotypic data comparing individuals with periodontal disease and periodontally healthy controls. Methodological quality was assessed using the Newcastle-Ottawa Scale (NOS), and the certainty of evidence was evaluated via the GRADE framework. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated under dominant genetic models. <b>Results:</b> Seven studies (n = 1467 participants) met the inclusion criteria. No eligible studies evaluated the 8473 T/C SNP. The meta-analysis of the -765 G/C variant revealed a significant association with periodontal disease (OR = 1.61; 95% CI: 1.12-2.32, <i>p</i> = 0.03; I<sup>2</sup> = 0%). For the -1195 G/A variant, the pooled OR was 1.86 (95% CI: 1.00-3.43, <i>p</i> = 0.05; I<sup>2</sup> = 35%), suggesting a borderline significant association. The certainty of evidence was graded as moderate for -765 G/C and low for -1195 G/A. <b>Conclusions:</b> The COX-2 -765 G/C polymorphism is significantly associated with increased CP risk, while the -1195 G/A variant shows a potential, though less certain, link. Larger, high-quality studies using standardized classifications are needed to confirm these associations.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"15 8","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12387893/pdf/","citationCount":"0","resultStr":"{\"title\":\"Association of Single Nucleotide Polymorphisms in the Cyclooxygenase-2 (COX-2) Gene with Periodontal Disease-A Systematic Review with Meta-Analysis and Implications for Personalized Dentistry.\",\"authors\":\"Vasiliki Savva, Ioannis Fragkioudakis, Dimitra Sakellari\",\"doi\":\"10.3390/jpm15080351\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Background:</b> Genetic polymorphisms in the cyclooxygenase-2 (COX-2) gene may contribute to individual susceptibility to periodontal disease. A meta-analysis assessed the association between three COX-2 single-nucleotide polymorphisms (SNPs) namely, -765 G/C (rs20417), -1195 G/A (rs689466), and 8473 T/C (rs5275), and the risk of CP. <b>Methods:</b> Following the PRISMA 2020 guidelines, we conducted a comprehensive search of five electronic databases and additional sources. The eligible studies were observational (case-control or cohort) with genotypic data comparing individuals with periodontal disease and periodontally healthy controls. Methodological quality was assessed using the Newcastle-Ottawa Scale (NOS), and the certainty of evidence was evaluated via the GRADE framework. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated under dominant genetic models. <b>Results:</b> Seven studies (n = 1467 participants) met the inclusion criteria. No eligible studies evaluated the 8473 T/C SNP. The meta-analysis of the -765 G/C variant revealed a significant association with periodontal disease (OR = 1.61; 95% CI: 1.12-2.32, <i>p</i> = 0.03; I<sup>2</sup> = 0%). For the -1195 G/A variant, the pooled OR was 1.86 (95% CI: 1.00-3.43, <i>p</i> = 0.05; I<sup>2</sup> = 35%), suggesting a borderline significant association. The certainty of evidence was graded as moderate for -765 G/C and low for -1195 G/A. <b>Conclusions:</b> The COX-2 -765 G/C polymorphism is significantly associated with increased CP risk, while the -1195 G/A variant shows a potential, though less certain, link. Larger, high-quality studies using standardized classifications are needed to confirm these associations.</p>\",\"PeriodicalId\":16722,\"journal\":{\"name\":\"Journal of Personalized Medicine\",\"volume\":\"15 8\",\"pages\":\"\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-08-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12387893/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Personalized Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3390/jpm15080351\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Personalized Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/jpm15080351","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
Association of Single Nucleotide Polymorphisms in the Cyclooxygenase-2 (COX-2) Gene with Periodontal Disease-A Systematic Review with Meta-Analysis and Implications for Personalized Dentistry.
Background: Genetic polymorphisms in the cyclooxygenase-2 (COX-2) gene may contribute to individual susceptibility to periodontal disease. A meta-analysis assessed the association between three COX-2 single-nucleotide polymorphisms (SNPs) namely, -765 G/C (rs20417), -1195 G/A (rs689466), and 8473 T/C (rs5275), and the risk of CP. Methods: Following the PRISMA 2020 guidelines, we conducted a comprehensive search of five electronic databases and additional sources. The eligible studies were observational (case-control or cohort) with genotypic data comparing individuals with periodontal disease and periodontally healthy controls. Methodological quality was assessed using the Newcastle-Ottawa Scale (NOS), and the certainty of evidence was evaluated via the GRADE framework. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated under dominant genetic models. Results: Seven studies (n = 1467 participants) met the inclusion criteria. No eligible studies evaluated the 8473 T/C SNP. The meta-analysis of the -765 G/C variant revealed a significant association with periodontal disease (OR = 1.61; 95% CI: 1.12-2.32, p = 0.03; I2 = 0%). For the -1195 G/A variant, the pooled OR was 1.86 (95% CI: 1.00-3.43, p = 0.05; I2 = 35%), suggesting a borderline significant association. The certainty of evidence was graded as moderate for -765 G/C and low for -1195 G/A. Conclusions: The COX-2 -765 G/C polymorphism is significantly associated with increased CP risk, while the -1195 G/A variant shows a potential, though less certain, link. Larger, high-quality studies using standardized classifications are needed to confirm these associations.
期刊介绍:
Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., pharmacogenomics/proteomics, systems biology). JPM recognizes that personalized medicine—the assessment of genetic, environmental and host factors that cause variability of individuals—is a challenging, transdisciplinary topic that requires discussions from a range of experts. For a comprehensive perspective of personalized medicine, JPM aims to integrate expertise from the molecular and translational sciences, therapeutics and diagnostics, as well as discussions of regulatory, social, ethical and policy aspects. We provide a forum to bring together academic and clinical researchers, biotechnology, diagnostic and pharmaceutical companies, health professionals, regulatory and ethical experts, and government and regulatory authorities.